FLCN and renal cell adenocarcinoma: To further test the efficacy of sirolimus on human FLCN-deficient RCC growth in vivo, we developed a xenograft mouse model by inoculating human FLCN-deficient RCC line, UOK 257-1, a cell line derived from a human BHD renal tumor [35].